Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 101

1.

The TNM 8th edition: Validation of the proposal for organ - confined (pT2) prostate cancer.

Billis A, Freitas LLL, Costa LBE, Barreto IS, Magna LA, Matheus WE, Ferreira U.

Int Braz J Urol. 2018 Nov 30;45. doi: 10.1590/S1677-5538.IBJU.2018.0338. [Epub ahead of print]

PMID:
30648826
2.

Prostate total tumor extent versus index tumor extent--which is predictive of biochemical recurrence following radical prostatectomy?

Billis A, Meirelles LR, Freitas LL, Polidoro AS, Fernandes HA, Padilha MM, Magna LA, Ferreira U.

J Urol. 2013 Jan;189(1):99-104. doi: 10.1016/j.juro.2012.08.179. Epub 2012 Nov 16.

PMID:
23164377
3.

Does index tumor predominant location influence prognostic factors in radical prostatectomies?

Billis A, Freitas LLL, Costa LBE, Angelis CM, Carvalho KR, Magna LA, Ferreira U.

Int Braz J Urol. 2017 Jul-Aug;43(4):686-697. doi: 10.1590/S1677-5538.IBJU.2016.0335.

4.

The prognostic role of the pathological T2 subclassification for prostate cancer in the 2002 Tumour-Nodes-Metastasis staging system.

van Oort IM, Witjes JA, Kok DE, Kiemeney LA, Hulsbergen-Van De Kaa CA.

BJU Int. 2008 Aug;102(4):438-41. doi: 10.1111/j.1464-410X.2008.07611.x. Epub 2008 Mar 11.

5.

Modification of the pT2 substage classification in prostate adenocarcinoma.

Ettel M, Kong M, Lee P, Zhou M, Melamed J, Deng FM.

Hum Pathol. 2016 Oct;56:57-63. doi: 10.1016/j.humpath.2016.05.016. Epub 2016 May 29.

PMID:
27251951
6.

Comparison of digital rectal examination and biopsy results with the radical prostatectomy specimen.

Obek C, Louis P, Civantos F, Soloway MS.

J Urol. 1999 Feb;161(2):494-8; discussion 498-9. Review.

PMID:
9915434
7.

Should pathologists continue to use the current pT2 substaging system for reporting of radical prostatectomy specimens?

Billis A, Meirelles LL, Freitas LL, Magna LA, Reis LO, Ferreira U.

Int Urol Nephrol. 2011 Sep;43(3):707-14. doi: 10.1007/s11255-011-9906-0. Epub 2011 Feb 20.

PMID:
21336958
8.

Improved clinical staging system combining biopsy laterality and TNM stage for men with T1c and T2 prostate cancer: results from the SEARCH database.

Freedland SJ, Presti JC Jr, Terris MK, Kane CJ, Aronson WJ, Dorey F, Amling CL; SEARCH Database Study Group.

J Urol. 2003 Jun;169(6):2129-35.

PMID:
12771734
9.

Prognostic significance of tumor volume in radical prostatectomy and needle biopsy specimens.

Epstein JI.

J Urol. 2011 Sep;186(3):790-7. doi: 10.1016/j.juro.2011.02.2695. Epub 2011 Jul 23. Review.

PMID:
21788055
10.

Biochemical failure after radical prostatectomy in men with pathologic organ-confined disease: pT2a versus pT2b.

Freedland SJ, Partin AW, Epstein JI, Walsh PC.

Cancer. 2004 Apr 15;100(8):1646-9.

11.

Prostate cancer - major changes in the American Joint Committee on Cancer eighth edition cancer staging manual.

Buyyounouski MK, Choyke PL, McKenney JK, Sartor O, Sandler HM, Amin MB, Kattan MW, Lin DW.

CA Cancer J Clin. 2017 May 6;67(3):245-253. doi: 10.3322/caac.21391. Epub 2017 Feb 21.

12.

Prognostic value of subclassification (pT2 stage) of pathologically organ-confined prostate cancer: Confirmation of the changes introduced in the 8th edition of the American Joint Committee on Cancer (AJCC) staging system.

Antunes HP, Parada B, Carvalho J, Eliseu M, Jarimba R, Oliveira R, Tavares-da-Silva E, Figueiredo A.

Arch Ital Urol Androl. 2018 Sep 30;90(3):191-194. doi: 10.4081/aiua.2018.3.191.

13.

Independent Validation of the American Joint Committee on Cancer 8th Edition Prostate Cancer Staging Classification.

Bhindi B, Karnes RJ, Rangel LJ, Mason RJ, Gettman MT, Frank I, Tollefson MK, Lin DW, Thompson RH, Boorjian SA.

J Urol. 2017 Dec;198(6):1286-1294. doi: 10.1016/j.juro.2017.06.085. Epub 2017 Jun 29.

PMID:
28669765
14.
15.

Predicting biochemical recurrence after radical prostatectomy for patients with organ-confined disease using p27 expression.

Freedland SJ, de Gregorio F, Sacoolidge JC, Elshimali YI, Csathy GS, Elashoff DA, Reiter RE, Aronson WJ.

Urology. 2003 Jun;61(6):1187-92.

PMID:
12809895
16.

Does Subclassification of Pathologically Organ Confined (pT2) Prostate Cancer Provide Prognostic Discrimination of Outcomes after Radical Prostatectomy?

Nguyen DP, Vertosick EA, Sharma V, Corradi RB, Vilaseca A, Takeda T, Sjoberg DD, Benfante N, Fine SW, Reuter VE, Scardino PT, Eastham JA, Karnes RJ, Touijer KA.

J Urol. 2018 Jun;199(6):1502-1509. doi: 10.1016/j.juro.2017.12.056. Epub 2018 Jan 4.

PMID:
29307681
17.

Presence of positive surgical margin in patients with organ-confined prostate cancer equals to extracapsular extension negative surgical margin. A plea for TNM staging system reclassification.

Abdollah F, Sun M, Suardi N, Gallina A, Capitanio U, Bianchi M, Tutolo M, Fossati N, Castiglione F, Freschi M, Karakiewicz P, Rigatti P, Montorsi F, Briganti A.

Urol Oncol. 2013 Nov;31(8):1497-503. doi: 10.1016/j.urolonc.2012.04.013. Epub 2012 May 15.

PMID:
22591746
18.

Positive margin length and highest Gleason grade of tumor at the margin predict for biochemical recurrence after radical prostatectomy in patients with organ-confined prostate cancer.

Chapin BF, Nguyen JN, Achim MF, Navai N, Williams SB, Prokhorova IN, Wang X, Tapia EMLN, Davis JW, Troncoso P.

Prostate Cancer Prostatic Dis. 2018 Jun;21(2):221-227. doi: 10.1038/s41391-017-0019-4. Epub 2017 Dec 11.

PMID:
29230008
19.

Influence of focal and diffuse extraprostatic extension and positive surgical margins on biochemical progression following radical prostatectomy.

Billis A, Meirelles LL, Freitas LL, Magna LA, Reis LO, Ferreira U.

Int Braz J Urol. 2012 Mar-Apr;38(2):175-84.

20.

Location, extent, and multifocality of positive surgical margins for biochemical recurrence prediction after radical prostatectomy.

Ploussard G, Drouin SJ, Rode J, Allory Y, Vordos D, Hoznek A, Abbou CC, de la Taille A, Salomon L.

World J Urol. 2014 Dec;32(6):1393-400. doi: 10.1007/s00345-014-1243-3. Epub 2014 Jan 21.

PMID:
24445447

Supplemental Content

Support Center